[Achievements and prospects of immunotherapy in urinary tract infection and pyelonephritis in children].
D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage; D002648:Child; D006801:Humans; D007108:Immune Tolerance; D007109:Immunity / Q000187:drug effects; D007114:Immunization / Q000379:methods; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D007978:Levamisole / Q000276:immunology / Q000627:therapeutic use; D011354:Prodigiozan / Q000276:immunology / Q000627:therapeutic use; D011704:Pyelonephritis / Q000628:therapy*; D013601:T-Lymphocytes / Q000187:drug effects; D013951:Thymus Hormones / Q000276:immunology / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000628:therapy*
D001428:Bacterial Vaccines; D013951:Thymus Hormones; D007978:Levamisole; D011354:Prodigiozan
Dostizheniia i perspektivy immunoterapii infektsii mochevykh puteĭ i pielonefrita u deteĭ.